<DOC>
	<DOC>NCT01773187</DOC>
	<brief_summary>The primary hypothesis of the study is that treatment with pacritinib results in a greater proportion of patients achieving ≥ 35% reduction in spleen volume from baseline to Week 24 than treatment with BAT.</brief_summary>
	<brief_title>Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<criteria>Intermediate 1 or 2 or highrisk Myelofibrosis (per Passamonti et al 2010) Palpable splenomegaly ≥ 5 cm on physical examination Total Symptom Score &gt;13 on the MPNSAF TSS 2.0, not including the inactivity question Patients who are platelet or red blood cell transfusiondependent are eligible Adequate white blood cell counts (with low blast counts), liver function, and renal function No spleen radiation therapy for 612 months Last therapy for myelofibrosis was 24 weeks ago, including any erythropoietic or thrombopoietic agent Not pregnant, not lactating, and agree to use effective birth control Prior treatment with a JAK2 inhibitor History of (or plans to undergo) spleen removal surgery or allogeneic stem cell transplant Ongoing gastrointestinal medical condition such as Crohn's disease, Inflammatory bowel disease, chronic diarrhea, or constipation Cardiovascular disease, including recent history or currently clinically symptomatic and uncontrolled: congestive heart failure, arrhythmia, angina, QTc prolongation or other QTc risk factors, myocardial infarction Other malignancy within last 3 years other than certain limited skin, cervical, prostate, breast, or bladder cancers Other ongoing, uncontrolled illnesses (including HIV infection and active hepatitis A, B, or C), psychiatric disorder, or social situation that would prevent good care on this study Life expectancy &lt; 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
	<keyword>Post-Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Polycythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Thrombocythemia, Essential</keyword>
	<keyword>Thrombocythemia</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Disease</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Splenomegaly</keyword>
	<keyword>Pacritinib</keyword>
	<keyword>MPN-SAF</keyword>
	<keyword>MPN-SAF TSS</keyword>
	<keyword>Anemia</keyword>
	<keyword>Myeloproliferative</keyword>
	<keyword>Myeloproliferative Neoplasm</keyword>
	<keyword>Spleen</keyword>
	<keyword>Spleen volume</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>SB1518</keyword>
</DOC>